CAR T Release Testing Basics
February 21, 2020
In the cell and gene therapy industry people often say that manufacturing is 80% of the business. Naturally, I continue to look for nuggets of wisdom from manufacturing experts. Recently, I had an opportunity to observe release testing for a fresh CAR T product at an academic institution with a state-of-the art cGMP cell therapy unit. In the process, technologists shared with me their guidelines, learnings, and rules of thumb. Clearly, it is impossible to ignore commercial and business development implications of the manufacturing process and quality control in this space.
CAR T Release Testing Criteria
Each product has pre-determined tests and release specifications. However, not all testing is mandatory for providing a product to patients. Mandatory tests include
  • Cell viability
  • % cells expressing CAR
  • Endotoxin
  • Microorganisms
  • Mycoplasma
  • Replication Competent Retrovirus (RCR)
Key Tests And Expert Opinion
The PDF table below describes key Tests, rough time needed for each test completion (under an hour, under a day, etc.), purpose of each test, and Release Specifications. Of these parameters, Tests and Release Specifications, along with results, are recorded in a Certificate of Analysis (CoA) for each product lot.

Table links: 7-AAD dye, LAL.
Graphical Outputs For Viability And CAR+%
Cell viability precedes CAR+% analysis to include only viable cells into further phenotyping.

Cell viability by flow cytometry

To calculate the volume of CAR T cells needed for injections, medical staff uses total % of CAR-positive cells and the dose per label or for a specific Dose Cohort per the IND Clinical Protocol.

Quantification of CAR-positive T cells in the product by flow cytometry
Additionally, phenotyping of CAR-T cells using other surface markers is performed, but is not required for product release to patients. Notably, such surface markers may include CD14, CD20, CD16/56, and so on.

We welcome any questions or requests at To find more interesting articles visit our Insights page.

Disclaimer: This article is meant for educational purposes only. BioHeights LLC and its members are not responsible for anybody’s anybody’s actions, losses, or damages resulting from reading this article.
Sickle Cell Disease: Centers of Excellence And Gene Therapy
July 11, 2020
Ohio Cell and Vector Manufacturing Landscape
May 15, 2020
Educational Webinars: Forecasting Principles And Tools
April 8, 2020
Risk-Adjusted NPV Calculator – Free Tool
March 21, 2020
NRA NPV Forecast For Investigational Product – Free Tool
March 11, 2020
CAR T Release Testing Basics
February 21, 2020
Revenue Forecast For Investigational Therapeutic – Free Tool
February 19, 2020
The Man Who Speaks on Behalf of ALL Children
October 17, 2019
Anti-CD19 CAR T Kymriah and Yescarta Race to Market Infographic
September 1, 2019
Jeff Marrazzo Tells His Spark Story
July 1, 2019
ASGCT 2019 Insights: Cell and Gene Therapies Tackle 160+ Disorders
May 10, 2019
AAV Gene Therapy Clinical Trials Target Over 50 Diseases
April 1, 2019
13 Different Routes of Administration in AAV Gene Therapy Clinical Trials
March 1, 2019